000661 长春高新
已收盘 07-28 15:00:00
资讯
新帖
简况
7月27日长春高新涨5.82%,生物医药ETF国泰基金重仓该股
证券之星 · 07-27 16:44
7月27日长春高新涨5.82%,生物医药ETF国泰基金重仓该股
长春高新最新公告:子公司注射用GenSci136临床试验申请获受理
证券之星 · 07-23
长春高新最新公告:子公司注射用GenSci136临床试验申请获受理
长春高新(000661)披露2026年限制性股票激励计划管理办法,7月22日股价上涨3.01%
证券之星 · 07-22
长春高新(000661)披露2026年限制性股票激励计划管理办法,7月22日股价上涨3.01%
7月16日长春高新涨5.40%,创新药ETF银华基金重仓该股
证券之星 · 07-16
7月16日长春高新涨5.40%,创新药ETF银华基金重仓该股
长春高新:预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元
证券之星 · 07-14
长春高新:预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元
长春高新最新公告:预计2026年半年度净利润同比下降40%-60%
证券之星 · 07-14
长春高新最新公告:预计2026年半年度净利润同比下降40%-60%
长春高新最新公告:子公司产品银花泌炎灵片新纳入国家基本药物目录
证券之星 · 07-10
长春高新最新公告:子公司产品银花泌炎灵片新纳入国家基本药物目录
7月10日长春高新涨5.48%,创新药ETF银华基金重仓该股
证券之星 · 07-10
7月10日长春高新涨5.48%,创新药ETF银华基金重仓该股
长春高新:以经营业绩为市值管理根本
证券之星 · 07-10
长春高新:以经营业绩为市值管理根本
长春高新(000661)披露子公司GenSci148注射液临床试验申请获受理公告,7月8日股价下跌0.91%
证券之星 · 07-08
长春高新(000661)披露子公司GenSci148注射液临床试验申请获受理公告,7月8日股价下跌0.91%
别让“家事”成为股市“公害”
财闻 · 07-08
别让“家事”成为股市“公害”
长春高新(000661)披露子公司GenSci164注射液临床试验申请获批公告,7月3日股价下跌0.22%
证券之星 · 07-03
长春高新(000661)披露子公司GenSci164注射液临床试验申请获批公告,7月3日股价下跌0.22%
长春高新最新公告:子公司GenSci164注射液临床试验申请获批准
证券之星 · 07-03
长春高新最新公告:子公司GenSci164注射液临床试验申请获批准
长春高新:公司稳步推进生长激素相关产品出海布局
证券之星 · 07-01
长春高新:公司稳步推进生长激素相关产品出海布局
长春高新:公司以经营业绩为市值管理根本
证券之星 · 07-01
长春高新:公司以经营业绩为市值管理根本
股市必读:长春高新(000661)6月30日董秘有最新回复
证券之星 · 07-01
股市必读:长春高新(000661)6月30日董秘有最新回复
6月29日长春高新涨7.88%,创新药ETF银华基金重仓该股
证券之星 · 06-29
6月29日长春高新涨7.88%,创新药ETF银华基金重仓该股
长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》
智通财经 · 06-22
长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》
股市必读:长春高新(000661)6月18日董秘有最新回复
证券之星 · 06-22
股市必读:长春高新(000661)6月18日董秘有最新回复
每周股票复盘:长春高新(000661)现1723.58万元大宗交易
证券之星 · 06-21
每周股票复盘:长春高新(000661)现1723.58万元大宗交易
加载更多
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":79.58,"timestamp":1785222213000,"preClose":79.8,"halted":0,"volume":10156289,"delay":0,"changeRate":-0.0028,"floatShares":400000000,"shares":408000000,"eps":-0.103,"marketStatus":"已收盘","change":-0.22,"latestTime":"07-28 15:00:00","open":79.45,"high":80.2,"low":77.5,"amount":800000000,"amplitude":0.0338,"askPrice":79.59,"askSize":61,"bidPrice":79.58,"bidSize":144,"shortable":0,"etf":0,"ttmEps":-0.103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785288600000},"marketStatusCode":5,"adr":0,"adjPreClose":79.8,"symbolType":"stock","openAndCloseTimeList":[[1785202200000,1785209400000],[1785214800000,1785222000000]],"highLimit":87.78,"lowLimit":71.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.46,"roa":"--","roe":"1.25%","epsLYR":0.39,"committee":0.240449,"marketValue":32464000000,"turnoverRate":0.0254,"status":1,"floatMarketCap":31801000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2654301349","title":"7月27日长春高新涨5.82%,生物医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654301349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654301349?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:44","pubTimestamp":1785141858,"startTime":"0","endTime":"0","summary":"证券之星消息,7月27日长春高新涨5.82%,收盘报79.8元,换手率2.76%,成交量11.02万手,成交额8.68亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共13家,其中持有数量最多的公募基金为国泰基金的生物医药ETF国泰。生物医药ETF国泰目前规模为37.03亿元,最新净值0.9923,较上一交易日下跌3.17%,近一年下跌8.08%。生物医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700021030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","000661","BK0188","BK0239","BK0046","BK0075","BK0028","512290"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745382","title":"长春高新最新公告:子公司注射用GenSci136临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745382","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653745382?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:49","pubTimestamp":1784800164,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》,注射用GenSci136的境内生产药品注册临床试验申请获得受理,拟用于治疗系统性红斑狼疮(SLE)。该药品为金赛药业自主研发的治疗用生物制品1类药物,采用全新分子结构和BAFF/APRIL双靶点作用机制,有望为SLE患者提供新的治疗选择。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0057","BK0028","BK0075","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653654897","title":"长春高新(000661)披露2026年限制性股票激励计划管理办法,7月22日股价上涨3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653654897","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653654897?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:04","pubTimestamp":1784729058,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘,长春高新报收于77.44元,较前一交易日上涨3.01%,最新总市值为315.91亿元。该股当日开盘75.18元,最高77.89元,最低74.28元,成交额达10.48亿元,换手率为3.44%。近日,长春高新技术产业(集团)股份有限公司披露《2026年限制性股票激励计划管理办法》。公告显示,该办法明确激励计划的管理机构、实施程序、特殊情形处理、信息披露及财务税收规定等内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0075","000661","BK0057","BK0188","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651412042","title":"7月16日长春高新涨5.40%,创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651412042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651412042?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:25","pubTimestamp":1784190337,"startTime":"0","endTime":"0","summary":"证券之星消息,7月16日长春高新涨5.40%,收盘报75.94元,换手率4.54%,成交量18.13万手,成交额13.45亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600026178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0028","BK0046","BK0075","159316","BK0188","BK0239","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651846105","title":"长春高新:预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651846105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651846105?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:12","pubTimestamp":1784031174,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新发布业绩预告,预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元。长春高新2026年一季报显示,一季度公司主营收入25.87亿元,同比下降13.69%;归母净利润2.76亿元,同比下降41.67%;扣非净利润2.82亿元,同比下降42.61%;负债率18.3%,投资收益-2782.4万元,财务费用901.48万元,毛利率77.95%。本文数据来源于《长春高新:2026年半年度业绩预告》,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400044486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651177581","title":"长春高新最新公告:预计2026年半年度净利润同比下降40%-60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651177581","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651177581?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:50","pubTimestamp":1784026219,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,预计2026年半年度归属于上市公司股东的净利润为3.93亿元-5.90亿元,同比下降40%-60%。业绩变动主要系新版国家医保目录实施后,公司长效生长激素等产品价格大幅下降,导致营业收入及净利润减少。注:公司Q2净利润预计1.17亿-3.14亿,Q1净利润2.76亿,据此计算,Q2净利润预计环比变动-57%-13%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400039575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650186094","title":"长春高新最新公告:子公司产品银花泌炎灵片新纳入国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2650186094","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650186094?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:30","pubTimestamp":1783675853,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司控股子公司吉林华康药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》,该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用,但短期内对公司业绩不会产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","BK0075","BK0057","000661","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183905","title":"7月10日长春高新涨5.48%,创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183905?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:27","pubTimestamp":1783672079,"startTime":"0","endTime":"0","summary":"证券之星消息,7月10日长春高新涨5.48%,收盘报69.5元,换手率3.69%,成交量14.76万手,成交额10.16亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159316","BK0028","BK0075","BK0046","BK0188","BK0239","BK0057","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650269188","title":"长春高新:以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2650269188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650269188?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:54","pubTimestamp":1783670059,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问一下公司跟跌不跟涨的原因是什么,最近公司有什么大雷还是什么原因。面对公司最近股票的走势,请问公司的应对方法是什么?长春高新回复:感谢您对公司的关注和建议。公司以经营业绩为市值管理根本,一直在努力提升经营质量,加快产品研发、销售力度,筑牢内在价值根基;也将在合规的基础上持续提升资本市场沟通力度,多措并举推动市值真实匹配企业内在价值,提振长期持股信心。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000026328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0188","BK0028","BK0075","BK0239","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649008991","title":"长春高新(000661)披露子公司GenSci148注射液临床试验申请获受理公告,7月8日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649008991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649008991?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:16","pubTimestamp":1783520183,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,长春高新报收于65.46元,较前一交易日下跌0.91%,最新总市值为267.04亿元。该股当日开盘66.1元,最高67.56元,最低65.31元,成交额达4.33亿元,换手率为1.63%。近日,长春高新子公司金赛药业收到国家药品监督管理局签发的《受理通知书》,其自主研发的GenSci148注射液境内生产药品注册临床试验申请已获受理。该事项符合公司在眼科领域的战略规划,但后续研发进程及结果存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0075","BK0046","BK0239","BK0188","BK0057","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649910099","title":"别让“家事”成为股市“公害”","url":"https://stock-news.laohu8.com/highlight/detail?id=2649910099","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649910099?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:53","pubTimestamp":1783518780,"startTime":"0","endTime":"0","summary":"A股又见“天价离婚”,又见股价跌停。大洋电机公告中称,诉讼与公司生产经营无关,不会对公司经营产生重大影响。此次大洋电机也公告称,目前案件尚未开庭审理,公司实际控制权是否变动存在不确定性。保护中小投资者,不能止于事后追责,更需事前扎紧制度的篱笆,让控制权变更的风险预期更透明,让“家事”不再轻易成为收割股民的“黑天鹅”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-08/doc-inihceir1560077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0156","BK0169","BK0014","601360","BK0239","BK0017","BK0084","BK0028","BK0075","002249","BK0201","000661","BK0217","BK0046","BK0224","BK0188","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648664368","title":"长春高新(000661)披露子公司GenSci164注射液临床试验申请获批公告,7月3日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648664368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648664368?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:50","pubTimestamp":1783090220,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,长春高新报收于68.96元,较前一交易日下跌0.22%,最新总市值为281.31亿元。该股当日开盘69.93元,最高70.38元,最低68.12元,成交额达5.62亿元,换手率为2.03%。近日,长春高新子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,其自主研发的GenSci164注射液获准开展治疗甲状旁腺功能减退症的境内生产药品注册临床试验。目前临床试验审批已获批准,后续进程及结果仍存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300046076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0188","BK0028","BK0075","BK0239","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634266","title":"长春高新最新公告:子公司GenSci164注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634266","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634266?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:10","pubTimestamp":1783077036,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到国家药监局核准签发的《药物临床试验批准通知书》,GenSci164注射液境内生产药品注册临床试验申请获得批准,拟用于治疗甲状旁腺功能减退症。该药品为金赛药业自主研发的PTH1R激动剂,属于治疗用生物制品1类,依托长效缓释多肽技术Duratide设计,旨在降低给药频率并稳定血钙和血磷水平。但药品研发周期长、风险高,后续进程及结果存在不确定性,投资者需注意风险。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300038845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","BK0057","BK0188","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515451","title":"长春高新:公司稳步推进生长激素相关产品出海布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515451?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:27","pubTimestamp":1782894448,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司长效生长激素出海情况如何?长春高新回复:公司稳步推进生长激素相关产品出海布局,同时根据不同国家、地区的行业、市场、政策等,持续挖掘海外市场增量,丰富长期价值增长点。对于具体销售数据情况,请持续关注公司定期报告等列示的相关内容,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0188","BK0046","BK0028","BK0057","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515910","title":"长春高新:公司以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515910","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515910?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:18","pubTimestamp":1782893900,"startTime":"0","endTime":"0","summary":"公司股价已经到了非常危险的程度 请不要说空话官话来回复投资者长春高新回复:感谢您对公司的关注和建议,我们会将您的意见转达给经营管理层。公司以经营业绩为市值管理根本,一直在努力提升经营质量,加快产品研发、销售力度,筑牢内在价值根基;也将在合规的基础上持续提升资本市场沟通力度,多措并举推动市值真实匹配企业内在价值,提振长期持股信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0188","BK0028","BK0075","BK0239","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648763565","title":"股市必读:长春高新(000661)6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648763565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648763565?lang=zh_cn&edition=full","pubTime":"2026-07-01 01:58","pubTimestamp":1782842293,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,长春高新报收于66.6元,下跌1.7%,换手率2.26%,成交量9.04万手,成交额5.99亿元。董秘最新回复投资者: 你好,公司二级市场股价近一年跌超55%,请公司认真考虑股东诉求,尽快安排回购注销,提升市场信心。同时,公司未来若有达到信息披露要求的市值管理相关举措安排,将严格履行决策程序并及时对外披露,谢谢!当日关注点交易信息汇总:6月30日主力资金净流出1889.91万元,游资资金净流入2143.98万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100001116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0188","BK0057","BK0239","BK0046","BK0075","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647628322","title":"6月29日长春高新涨7.88%,创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647628322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647628322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:48","pubTimestamp":1782722904,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日长春高新涨7.88%创60日新低,收盘报67.75元,换手率3.87%,成交量15.48万手,成交额10.24亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0075","BK0028","BK0046","159316","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645407460","title":"长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2645407460","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645407460?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:53","pubTimestamp":1782118419,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司控股子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药品注册证书》,金赛药业注射用醋酸曲普瑞林(II)的境内生产药品注册上市许可申请获得批准。该药品适用于体重20kg及以上儿童中枢性性早熟(CPP)治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0028","BK0046","000661","BK0075","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645873015","title":"股市必读:长春高新(000661)6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645873015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645873015?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:35","pubTimestamp":1782066917,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,长春高新报收于64.1元,上涨0.49%,换手率1.7%,成交量6.81万手,成交额4.38亿元。董秘最新回复投资者: 股价持续下跌,公司高层没有解决方案吗?长春高新信用目前处于哪一个等级。当日关注点交易信息汇总:6月18日主力资金净流出1520.79万元,散户资金净流入1947.18万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0239","000661","BK0075","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095479","title":"每周股票复盘:长春高新(000661)现1723.58万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095479","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095479?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:11","pubTimestamp":1781979070,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,长春高新(000661)报收于64.1元,较上周的66.5元下跌3.61%。本周,长春高新6月15日盘中最高价报66.39元。6月18日盘中最低价报63.01元,股价触及近一年最低点。长春高新当前最新总市值261.49亿元,在生物制品板块市值排名8/51,在两市A股市值排名834/5206。本周关注点交易信息汇总:6月15日长春高新现1723.58万元大宗交易交易信息汇总6月15日长春高新现1723.58万元大宗交易以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0046","000661","BK0075","BK0057"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785251407858,"stockEarnings":[{"period":"1week","weight":0.0854},{"period":"1month","weight":0.2707},{"period":"3month","weight":-0.0659},{"period":"6month","weight":-0.1791},{"period":"1year","weight":-0.2293},{"period":"ytd","weight":-0.136}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":-0.042},{"period":"3month","weight":-0.054},{"period":"6month","weight":-0.0706},{"period":"1year","weight":0.0736},{"period":"ytd","weight":-0.0279}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"138133人(较上一季度增加7.70%)","perCapita":"2892股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}